

Supporting Information

**Hand-powered Centrifugal Microfluidic Platforms Inspired by a Spinning Top  
for Sample-to-Answer Diagnostics of Nucleic Acids**

Lu Zhang,<sup>1‡★</sup> Fei Tian,<sup>2,4‡</sup> Chao Liu,<sup>2,3</sup> Qiang Feng,<sup>2,3</sup> Tingxuan Ma,<sup>1</sup> Zishan Zhao,<sup>1</sup>  
Tiejun Li,<sup>4</sup> Xingyu Jiang<sup>2,3★</sup> and Jiashu Sun<sup>2,3★</sup>

<sup>1</sup>Department of Chemistry, Capital Normal University, Beijing 100048, P. R. China

<sup>2</sup>CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS  
Center for Excellence in Nanoscience, National Center for Nanoscience and  
Technology, Beijing 100190, P. R. China


<sup>3</sup>University of Chinese Academy of Sciences, Beijing 100049, P. R. China

<sup>4</sup>School of Mechanical Engineering, Hebei University of Technology, Tianjin 300401,  
P. R. China


E-mail address: zhangl@cnu.edu.cn (L. Zhang); xingyujiang@nanoctr.cn (X.Y.  
Jiang); sunjs@nanoctr.cn (J.S. Sun)

Tel:+86-10-82545621; Fax: +86-10-82545621


‡These authors contributed equally to this work.



**Figure S1.** On-chip capillary valves for liquid control. (a) Schematic of 3D (expansion structure in both the horizontal plane and the vertical plane) and 2D (expansion structure in the horizontal plane) capillary valves. (b) Photograph of 3D capillary valves that can prevent the mixing of different color dyes from different chambers (C1, C2 and C3) under stagnant conditions, whereas 2D capillary valves cannot block the flow of dyes between different chambers. Scale bar, 5 mm.



**Figure S2.** The availability and specificity of primers verified by LAMP reaction in tubes. After 1 h amplification, the solutions with target plasmids (left) generate strong fluorescence, while the solutions without plasmids (right) remain dark under UV excitation at 365 nm.



**Figure S3.** Photograph of the microfluidic disc for multiplex detection of nucleic acids in bacteria after 3-day storage at room temperature. The preserved fluorescent signals could facilitate the re-checking of assay results in clinical diagnosis.

**Table S1. Nucleotide sequences of the conserved fragments of pathogenic bacteria.**

Name	Target fragment sequence (5' to 3')
P. aeruginosa (191 bp) oprL gene (Accession Number: Z50191, 810-1000)	GCGTTGCCGCCAACAAATGGCGGCAACGTTCT CCTTCCGGGTATGGCACGGCAGGTGCCGGCG CGCCTTACCGGAGGTGGGTGACAACCCCCA CCTCCGTGCAGGGCGAACTGTTCATGCAGCTC CAGCAGATGCAGGACGAGTTGGCTGCCTGCG TGGCACGCTCGAGCGAGAGAGTTGCCGCATG
S. Typhimurium (244 bp) invA gene (Accession Number: M90846, 225-468)	GGCGATATTGGTGTATGGGTCGTTACAT TGACAGAACCTCAGTTTCAACGTTCTGC GGTACTGTTAATTACCACGCTTTCTGCTGGC ATTATCGATCAGTACCAAGCTGTCTTATCTTGAT TGAAGCCGATGCCGGTGAAATTATGCCACGT TCGGGCAATTCTGTTATTGGCGATAGCCTGGCG GTGGGTTTGTGTCTCTATTGTCACCGTG GTCCAGTTATCGTT
V.parahaemolyticus (229 bp) thermolabile hemolysin gene (Accession Number: M36437, 283-511)	AGCTACTCGAAAGATGATCCAGCGACCGATTG GGAATGGGCAAAAAACGAAGATGGTAGCTACT TCACCATTGACGGCTACTGGTGGAGCTCCGTT CATTAAAAACATGTTCTACACCAACACGTCG CAAAACGTTATCCGTAGCGTTGTGAAGCAAC ATTAGATTGGCGAACGAGAACGAGACACATTA CGTTCTCGCCGCTGACAATCGCTCTCATACA ACC
V. vulnificus (308 bp) outer membrane protein TolC gene (Accession Number: DQ296643, 999-1306)	TCTTGAAGCCACTTATCGCGGTGTCGTGAAAG AAGTGCAGCGCAAAACAACACATCAATGCC TCAATCGGTGCACTCGTGCCTATGAGCAATCT GTTGTTCTGCGCGTTCAGCATTAGAAGCAACC GAAGCGGGCTTGATGTTGGTACTCGTACTATT GTGGATGTACTTGATGCCACTCGTCGCCTTAC GATGCCAACAAAAACCTATCGAATGCACGCTA CAACTACATCTTGAGTGTACTGCAACTCGTCA GGCGGTGGGTACACTGAGCGAGCAAGATGTAC TGGATGTTGATGCTG
S. iniae (271 bp) DNA gyrase subunit B	GAAGATGATTCCATTACCGTTGATGATGGC CGTGGGATTCTGTTGATATTCAAGAAAAAC

gene (Accession Number: KC560771, 220-490)	GGGTCGACCTGCTGTTGAAACAGTCTTACAGT TCTCCATGCTGGAGGTAAATTGGCGGAGGCG GTTATAAGGTTCAGGTGGTCTGCATGGGGTTG GTTCATCAGTTGTTAATGCCCTCTCAACACAGT TAGATGTCCGGGTTATAAAAATGGAAATATC TACTATCAAGAATTAAACGTGGTGTGGTAGG AGAAGATTAG
V. alginolyticus (232 bp) Outer membrane protein gene (Accession Number: GU318325, 162-393)	CTACCTAGAAATGGAATTGGCGGCCGCTCTG GTATCTCGACCTTACGGCTACGTTGATGTAT TCAACCTAACCTCTGATCCAGGTAGCGACAAA GCTGGCGCAGAGAAGATCTTATGAAATT CGC TCCACGTATGTCTCTAGATGCGGTAAGTGGTAA AGACCTATCTTCGGTCCAGTTCAAGAGCTATA CGTTGCAACTCTAATCGAGTGGGGTGGTAAGT CTGGT

**Table S2. LAMP primers for pathogen detection.**

Primer name	Sequence (5' to 3')
P. aeruginosa-F3	GCGTTGCCGCCAACAAATG
P. aeruginosa-B3	CATGCAGGGCAACCTCTC
P. aeruginosa-FIP	GTTGTCACCCCACCTCCGGCGGCAACGTTCC CC
P. aeruginosa-BIP	CTCCGTGCAGGGCGAACTGCAGGCGAGCCAAC TC
P. aeruginosa-LF	ACCTGCCGTGCCATACC
P. aeruginosa-LB	GTTCATGCAGCTCCAGCAG
S. Typhimurium-F3	GGCGATATTGGTGTATGGGG
S. Typhimurium-B3	AACGATAAACTGGACCACGG
S. Typhimurium-FIP	GACGACTGGTACTGATCGATAGTTTCAACGT TTCCTGCGG
S. Typhimurium-BIP	CCGGTGAAATTATGCCACACAAAACCCACCG CCAGG
S. Typhimurium-LF	GACGAAAGAGCGTGGTAATTAAC
S. Typhimurium-LB	GGGCAATTCTGTTATTGGCGATAG
V.parahaemolyticus-F3	AGCTACTCGAAAGATGATCC
V.parahaemolyticus-B3	GGTTGTATGAGAAGCGATTG
V.parahaemolyticus-FIP	ATGTTTTAAATGAAACGGAGCTCCGGCAAAA AACGAAGATGGT
V.parahaemolyticus-BIP	ACGTCGAAAACGTTATCCGGCGAAGAACGTA ATGTCTG
V.parahaemolyticus-LF	ACCAGTAGCCGTCAATG
V.parahaemolyticus-LB	TTAGATTGGCGAACGAGA
V. vulnificus-F3	TCTTGAAGCCACTTATCGC

<i>V. vulnificus</i> -B3	CAGCATCACATCCAGTACA
<i>V. vulnificus</i> -FIP	TACCAACATCAAAGCCCGCTTtttCGTGCCTATG AGCAATCT
<i>V. vulnificus</i> -BIP	GATGCCACTCGTCGCCTTtttGCAGTACACTCAA GATGTAGTT
<i>V. vulnificus</i> -LF	GGTGCTTCTAATGCTGAACG
<i>V. vulnificus</i> -LB	AACCTATCGAATGCACGCT
<i>S. iniae</i> -F3	GAAGATGATTCCATTACCGTTG
<i>S. iniae</i> -B3	CTAAATCTCTCCTACCACACC
<i>S. iniae</i> -FIP	TGAAACCTTATAACCGCCTCCGtttCTGCTGTTG AACAGTCTTAC
<i>S. iniae</i> -BIP	GGTCTGCATGGGGTTGGTTtttAACC CGGACATC TAACTGT
<i>S. iniae</i> -LF	TACCTCCAGCATGGAGAACT
<i>S. iniae</i> -LB	TCAGTTGTTAATGCCCTCTCAA
<i>V. alginolyticus</i> -F3	ACCAGAGTTACCACCCCCAC
<i>V. alginolyticus</i> -B3	CTACCTAGAAATGGAATT CGG
<i>V. alginolyticus</i> -FIP	GTATGTCTCTAGATGC GGTA ACTGGTtttCGATT AGAGTTGCAACGTATAGC
<i>V. alginolyticus</i> -BIP	GTCGCTACCTGGATCAGAAGTTAGGtttCGGCC GCTCTGGTATCTCGAC
<i>V. alginolyticus</i> -LB	TGAATACATCAACGTAGCCGTAAAG

---